Biolegend, 100734, PerCP/Cyanine5.5 anti-mouse CD8a Antibody, 100μg

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration: 0.2 mg/mL
Storage & Handling: The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is < 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed Schuster M, et al. 2017. J Immunol. 199:920. PubMed Yoon J et al. 2018. J Vis Exp. -141 . PubMed Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed Lang J, et al. 2020. Nat Commun. 11:1338. PubMed Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed Ferapontov A, et al. 2023. Nat Commun. 14:976. PubMed Shi X, et al. 2023. iScience. 26:106143. PubMed Pattnaik A, et al. 2023. Vaccines (Basel). 11:. PubMed Abdelwahab T, et al. 2023. iScience. 26:106698. PubMed Milighetti M, et al. 2023. iScience. 26:106937. PubMed Hu Y, et al. 2023. JCI Insight. 8:. PubMed Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed Goncharov NV, et al. 2022. J Evol Biochem Physiol. 58:230. PubMed Wemlinger SM, et al. 2022. J Immunol. 208:1566. PubMed Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed Silva Pereira S, et al. 2022. Elife. 11: . PubMed Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Ge Y, et al. 2022. iScience. 25:105437. PubMed Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed Ai L, et al. 2023. Cell Discov. 9:9. PubMed Chen L, et al. 2023. Bioeng Transl Med. 8:e10377. PubMed Teymournejad O, et al. 2023. NPJ Vaccines. 8:3. PubMed Marritt KL, et al. 2023. Front Immunol. 13:1087991. PubMed Wang R, et al. 2023. iScience. 26:105954. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed Cornax I, et al. 2021. Microorganisms. 9:00. PubMed Zhou J, et al. 2019. Immunity. 50:403. PubMed Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed Murata A, et al. 2020. Front Immunol. 11:775. PubMed Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed Barry KC, et al. 2018. Nat Med. 24:1178. PubMed Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed Kim CJ, et al. 2018. Immunity. 49:1034. PubMed Aldon Y, et al. 2020. J Immunol. 204:903. PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed Juul-Madsen K, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed Hong JY, et al. 2020. Cell. 180(5):847-861. PubMed Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed Solanki A, et al. 2018. Development. 145. PubMed Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed Green DP, et al. 2019. Neuron. 101:412. PubMed Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Smith AS, et al. 2022. J Immunother Cancer. 10:. PubMed Agrawal M, et al. 2021. Cells. 10:. PubMed Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed Xu J et al. 2018. Cell. 173(3):762-775 . PubMed Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed Shi R, et al. 2022. Theranostics. 12:875. PubMed Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed Pilzecker B, et al. 2016. Nucleic Acids Res. 44: 4734 - 4744. PubMed Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed Tondini E, et al. 2022. NPJ Vaccines. 7:64. PubMed Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed Chen X, et al. 2021. Cell Rep. 37:109991. PubMed Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed White C, et al. 2015. J Immunol. 194:697. PubMed Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed Chung L et al. 2018. Cell host & microbe. 23(2):203-214 . PubMed Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed Alameh MG, et al. 2021. Immunity. 54:2877. PubMed Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed Shi R, et al. 2019. J Cancer. 10:367. PubMed Karandikar SH, et al. 2019. JCI Insight. 5. PubMed Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed Yu H, et al. 2021. Front Oncol. 11:736882. PubMed Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed Wang Y, et al. 2020. Virol Sin. 36:122. PubMed Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed Tang Y, et al. 2019. Nat Commun. 10:4157. PubMed Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed Highton AJ, et al. 2019. Wellcome Open Res. 4:78. PubMed Liu YG, et al. 2019. FASEB J. 33:5018. PubMed Yao C, et al. 2018. Autophagy. 1.854861111. PubMed Li E, et al. 2021. Front Immunol. 12:667177. PubMed Mezzapelle R, et al. 2021. EMBO Mol Med. 13:e12344. PubMed Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed Woodring T, et al. 2022. iScience. 25:104934. PubMed Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed Bennion BG, et al. 2019. J Virol. 93. PubMed Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed Yin X, et al. 2020. Cell Rep. 33:108278. PubMed Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed Field CS, et al. 2020. Cell Metab. 31:422. PubMed Ireland L, et al. 2020. Front Immunol. 11:297. PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed Sun Y, et al. 2020. J Immunol. 205:2649. PubMed Zhang Z, et al. 2020. Nature. 579:415. PubMed Le QV, et al. 2022. Bioact Mater. 15:160. PubMed Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed Guo X, et al. 2020. J Cell Mol Med. . PubMed Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed Sun Y, et al. 2022. iScience. 25:104846. PubMed Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed Teng F, et al. 2021. Cell Rep. 37:110051. PubMed Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed Goc J, et al. 2021. Cell. 184:5015. PubMed Li A, et al. 2018. Cancer Lett. 431:54. PubMed Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed Wolf Y, et al. 2019. Cell. 179:219. PubMed Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
RRID: AB_2075239 (BioLegend Cat. No. 100733) AB_2075238 (BioLegend Cat. No. 100734)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ
Q: How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?
A: PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.